MCID: PLY041
MIFTS: 56

Polymyositis

Categories: Rare diseases, Neuronal diseases, Nephrological diseases, Bone diseases, Respiratory diseases

Aliases & Classifications for Polymyositis

MalaCards integrated aliases for Polymyositis:

Name: Polymyositis 53 54 59 55 73
Pm 59

Characteristics:

Orphanet epidemiological data:

59
polymyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Argentina),1-9/100000 (Argentina),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Spain),1-9/1000000 (Sweden); Age of onset: Adult,Elderly; Age of death: adult;

Classifications:



Summaries for Polymyositis

NINDS : 54 Polymyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Polymyositis affects skeletal muscles (those involved with making movement) on both sides of the body.  It is rarely seen in persons under age 18; most cases are in adults between the ages of 31 and 60.  Progressive muscle weakness starts in the proximal muscles (muscles closest to the trunk of the body) which eventually leads to difficulties climbing stairs, rising from a seated position, lifting objects, or reaching overhead.  People with polymyositis may also experience arthritis, shortness of breath, difficulty swallowing and speaking, and heart arrhythmias.  In some cases of polymyositis, distal muscles (muscles further away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Polymyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus.  Polymyositis may also be associated with infectious disorders, such as HIV-AIDS.

MalaCards based summary : Polymyositis, also known as pm, is related to inclusion body myositis and diffuse large b-cell lymphoma. An important gene associated with Polymyositis is RN7SL1 (RNA, 7SL, Cytoplasmic 1
Autoantibodies against signal recognition particle (SRP) are detected in patients with polymyositis/dermatomyositis (PM/DM). The SRP consists of 7SL RNA and 6 protein components.
Dysfunction Pattern: Interaction), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Abatacept and Pirfenidone have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and skeletal muscle, and related phenotypes are abnormality of the renal tubule and chondrocalcinosis

NIH Rare Diseases : 53 Polymyositis is a type of inflammatory myopathy, which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. The muscles affected by polymyositis are the skeletal muscles (those involved with making movements) on both sides of the body. Although the disease can affect people of all ages, most cases are seen in adults between the ages of 31 and 60 years. The disease is more common among women and among black individuals.  The exact cause of polymyositis is unknown. The disease shares many characteristics with autoimmune disorders, which occur when the immune system mistakenly attacks healthy body tissues. In some cases, the disease may be associated with viral infections, connective tissue disorders, or an increased risk for malignancies (cancer). Diagnosis is based on a clinical examination that may include laboratory tests, imaging studies, electromyography, and a muscle biopsy. Although there is no cure for polymyositis, treatment with corticosteroids or immunosuppressants can improve muscle strength and function.

Wikipedia : 76 Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to... more...

Related Diseases for Polymyositis

Diseases in the Polymyositis family:

Juvenile Polymyositis

Diseases related to Polymyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 259)
# Related Disease Score Top Affiliating Genes
1 inclusion body myositis 29.6 MIR146B MIR155 MIR21 MIR222
2 diffuse large b-cell lymphoma 28.4 MIR127 MIR155 MIR21 MIR210
3 pancreatic cancer 27.9 MIR127 MIR155 MIR21 MIR210 MIR222
4 ovarian cancer 27.7 MIR146B MIR155 MIR21 MIR210 MIR222
5 dermatomyositis 27.6 MIR132 MIR146B MIR21 MIR210 MIR222 MIR362
6 hepatocellular carcinoma 27.5 MIR127 MIR130A MIR132 MIR155 MIR21 MIR222
7 lung cancer 26.8 MIR130A MIR146B MIR155 MIR21 MIR210 MIR222
8 muscular dystrophy, duchenne type 26.6 MIR146B MIR155 MIR210 MIR222 MIR379 MIR382
9 juvenile polymyositis 12.3
10 myositis 11.5
11 mixed connective tissue disease 11.4
12 childhood type dermatomyositis 11.2
13 idiopathic inflammatory myopathy 11.2
14 tropical spastic paraparesis 11.2
15 myelopathy, htlv-1-associated 11.2
16 antisynthetase syndrome 11.2
17 necrotizing autoimmune myopathy 11.2
18 retrovirus-associated myelopathy 10.8
19 nonalcoholic fatty liver disease 10.4 MIR130A MIR132
20 lung disease 10.3
21 interstitial lung disease 10.3
22 kidney cancer 10.2 MIR21 MIR210
23 myopathy 10.1
24 pneumonia 10.1
25 arthritis 10.1
26 scleroderma, familial progressive 10.1
27 rheumatoid arthritis 10.1
28 hepatitis 10.0
29 myasthenia gravis 10.0
30 myasthenia gravis congenital 10.0
31 myocarditis 10.0
32 autism spectrum disorder 10.0 MIR132 MIR146B MIR21
33 connective tissue disease 10.0
34 lupus erythematosus 10.0
35 lymphoma 9.9
36 systemic lupus erythematosus 9.9
37 thymoma 9.9
38 adult dermatomyositis 9.9
39 fasciitis 9.9
40 muscular dystrophy 9.9
41 type i 9.8
42 purpura 9.8
43 hypothyroidism 9.8
44 oral squamous cell carcinoma 9.8 MIR132 MIR155 MIR21
45 vasculitis 9.8
46 autoimmune hepatitis 9.8
47 graft-versus-host disease 9.8
48 glomerulonephritis 9.8
49 lymphoma, hodgkin, classic 9.8 MIR155 MIR21
50 leukemia 9.8

Comorbidity relations with Polymyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Dermatomyositis Heart Disease
Hypertension, Essential Hypothyroidism
Osteoporosis Temporal Arteritis

Graphical network of the top 20 diseases related to Polymyositis:



Diseases related to Polymyositis

Symptoms & Phenotypes for Polymyositis

Human phenotypes related to Polymyositis:

59 32 (show all 42)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the renal tubule 59 32 occasional (7.5%) Occasional (29-5%) HP:0000091
2 chondrocalcinosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000934
3 muscular hypotonia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001252
4 gait disturbance 59 32 occasional (7.5%) Occasional (29-5%) HP:0001288
5 reduced tendon reflexes 59 32 occasional (7.5%) Occasional (29-5%) HP:0001315
6 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
7 dysphonia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001618
8 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
9 hypertrophic cardiomyopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001639
10 dilated cardiomyopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001644
11 myocardial infarction 59 32 occasional (7.5%) Occasional (29-5%) HP:0001658
12 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
13 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
14 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
15 constipation 59 32 frequent (33%) Frequent (79-30%) HP:0002019
16 gastroesophageal reflux 59 32 occasional (7.5%) Occasional (29-5%) HP:0002020
17 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
18 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
19 respiratory insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002093
20 pulmonary fibrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002206
21 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
22 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
23 vasculitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002633
24 arthralgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002829
25 exertional dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002875
26 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
27 breast carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0003002
28 elevated serum creatine phosphokinase 59 32 hallmark (90%) Very frequent (99-80%) HP:0003236
29 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
30 emg abnormality 59 32 hallmark (90%) Very frequent (99-80%) HP:0003457
31 proximal muscle weakness 59 32 hallmark (90%) Very frequent (99-80%) HP:0003701
32 abnormality of muscle fibers 59 32 hallmark (90%) Very frequent (99-80%) HP:0004303
33 venous thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004936
34 abnormal atrioventricular conduction 59 32 occasional (7.5%) Occasional (29-5%) HP:0005150
35 interstitial pulmonary abnormality 59 32 frequent (33%) Frequent (79-30%) HP:0006530
36 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
37 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
38 elevated aldolase level 59 32 hallmark (90%) Very frequent (99-80%) HP:0012544
39 cough 59 32 hallmark (90%) Very frequent (99-80%) HP:0012735
40 abnormality of the voice 59 Occasional (29-5%)
41 abnormality of the mitral valve 59 Occasional (29-5%)
42 abnormal mitral valve morphology 32 occasional (7.5%) HP:0001633

Drugs & Therapeutics for Polymyositis

Drugs for Polymyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
2
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
3 beta-endorphin Phase 4,Phase 2
4 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Adrenocorticotropic Hormone Phase 4,Phase 2
6 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1
9 Vaccines Phase 4,Phase 2
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Melanocyte-Stimulating Hormones Phase 4,Phase 2
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
18
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
19
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
20
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
21
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
22
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
23
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
24
Infliximab Approved Phase 2, Phase 3 170277-31-3
25
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
26
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
27
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1 185243-69-0
28
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492
29
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
30
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
31
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
32
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
35
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
36 tannic acid Approved, Nutraceutical Phase 2, Phase 3
37 Prednisolone acetate Phase 3,Phase 2
38 glucocorticoids Phase 3,Phase 2,Phase 1
39 Methylprednisolone acetate Phase 3,Phase 2
40 Methylprednisolone Hemisuccinate Phase 3,Phase 2
41 Folic Acid Antagonists Phase 3,Phase 2
42 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
43 Neuroprotective Agents Phase 3,Phase 2
44 Cyclosporins Phase 3,Phase 2
45 Dermatologic Agents Phase 3,Phase 2
46 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
47 Vitamin B Complex Phase 3,Phase 2
48 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
49 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
50 Prednisolone hemisuccinate Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
4 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
5 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
6 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
7 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
8 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
9 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
10 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
11 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
12 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
13 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
14 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
15 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
16 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
17 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3 Octagam 10%
18 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
19 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
20 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
21 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
22 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
23 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
24 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
25 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
26 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
27 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
28 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
29 Safety and Efficacy of BAF312 in Dermatomyositis Completed NCT02029274 Phase 2 BAF312 0.5 mg;BAF312 2 mg;BAF312 10 mg;Placebo to BAF312
30 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
31 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb
32 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
33 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2 tocilizumab;placebo
34 Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis Recruiting NCT03529955 Phase 2 Apremilast 30mg
35 A Study In Adults With Moderate To Severe Dermatomyositis Recruiting NCT03181893 Phase 2 PF-06823859;Placebo Arm
36 Study of IFN-K in Dermatomyositis Recruiting NCT02980198 Phase 2
37 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
38 Trial of IMO-8400 in Adult Patients With Dermatomyositis Active, not recruiting NCT02612857 Phase 2 IMO-8400 Dose Group 1;IMO-8400 Dose Group 2;Placebo
39 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Active, not recruiting NCT02466243 Phase 2 JBT-101;Placebo
40 Basiliximab Treating Interstitial Pneumonia of CADM Not yet recruiting NCT03192657 Phase 2 Basiliximab;Calcineurin Inhibitors;Steroids
41 Intralesional Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study Not yet recruiting NCT03582800 Phase 2 STS
42 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2 denosumab
43 Efficacy and Tolerability of BAF312 in Patients With Polymyositis Terminated NCT01801917 Phase 2 Placebo;BAF312
44 Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2 BAF312;Placebo
45 Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis Unknown status NCT00230204 Phase 1
46 A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1
47 A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Completed NCT02780674 Phase 1
48 Mycophenolate Mofetil in Systemic Sclerosis Completed NCT00433186 Phase 1 Mycophenolate Mofetil
49 A Pilot Study of Etanercept in Dermatomyositis Completed NCT00112385 Phase 1 Etanercept;Placebo
50 Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders Completed NCT00010335 Phase 1

Search NIH Clinical Center for Polymyositis

Genetic Tests for Polymyositis

Anatomical Context for Polymyositis

MalaCards organs/tissues related to Polymyositis:

41
Lung, Heart, Skeletal Muscle, Testes, T Cells, Bone, Skin

Publications for Polymyositis

Articles related to Polymyositis:

(show top 50) (show all 870)
# Title Authors Year
1
Tofacitinib for the Treatment of Refractory Polymyositis. ( 29794877 )
2018
2
The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study. ( 29977547 )
2018
3
Targeted lipidomics analysis identified altered serum lipid profiles in patients with polymyositis and dermatomyositis. ( 29720222 )
2018
4
A patient with pembrolizumab-induced fatal polymyositis. ( 29329695 )
2018
5
[<sup>18</sup>F]Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosing polymyositis/dermatomyositis. ( 29805526 )
2018
6
Roles of macrophage migration inhibitory factor in polymyositis: Inflammation and regeneration. ( 29239244 )
2018
7
Coexistence of anti-Jo1 and anti-signal recognition particle antibodies in a polymyositis patient. ( 29396013 )
2018
8
Symptomatic arrhythmia in the form of multiple premature ventricular extrasystoles as the first symptom of polymyositis. ( 29380919 )
2018
9
Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. ( 29293605 )
2018
10
Malignancy in a retrospective cohort of 17 patients with Dermatomyositis or Polymyositis in southern Tunisia. ( 29791319 )
2018
11
Respiratory insufficiency from myasthenia gravis and polymyositis due to malignant thymoma triggering Takotsubo syndrome. ( 29883223 )
2018
12
Cluster Analysis Using Anti-Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients With Polymyositis/Dermatomyositis. ( 29933322 )
2018
13
The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. ( 29325580 )
2018
14
Giant Cell Polymyositis and Myocarditis in a Patient With Thymoma and Myasthenia Gravis: A Postviral Autoimmune Process? ( 29850899 )
2018
15
Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. ( 29321815 )
2018
16
Autologous Bone Marrow Transplantation for Polymyositis Combined with Myasthenia Gravis and Aplastic Anemia: A Case Report. ( 29805377 )
2018
17
Hyaluronic acid in dermatomyositis and polymyositis: relationship with disease and cutaneous lesions. ( 29641701 )
2018
18
Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. ( 28993346 )
2018
19
Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases. ( 29657141 )
2018
20
Pure erythroid leukemia in a polymyositis patient treated with azathioprine. ( 29785257 )
2018
21
Ultrasound: A Potential Tool for Detecting of Fasciitis in Dermatomyositis and Polymyositis. ( 29496919 )
2018
22
MicroRNA-381 reduces inflammation and infiltration of macrophages in polymyositis via downregulating HMGB1. ( 29956737 )
2018
23
A Viral Polymyositis Masquerade: Life-Threatening Case of Juvenile Dermatomyositis Complicated by Systemic Capillary Leak Syndrome. ( 29720802 )
2018
24
Musculoskeletal Manifestations of Non-RA Connective Tissue Diseases: Scleroderma, Systemic Lupus Erythematosus, Still's Disease, Dermatomyositis/Polymyositis, SjAPgren's Syndrome, and Mixed Connective Tissue Disease. ( 29672805 )
2018
25
Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review. ( 29027009 )
2018
26
Limb-girdle muscular dystrophy type 2B misdiagnosed as polymyositis at the early stage: Case report and literature review. ( 29794729 )
2018
27
Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis. ( 29416342 )
2018
28
The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. ( 29703532 )
2018
29
Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies. ( 29289262 )
2018
30
Current diagnosis and treatment of polymyositis and dermatomyositis. ( 29669460 )
2018
31
Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: A retrospective case-control study. ( 29474373 )
2018
32
Role of Positron Emission Tomography-computed Tomography in a Case of Suspected Paraneoplastic Inflammatory Polymyositis with Urinary Bladder Tumor. ( 29430120 )
2018
33
Muscle Strength and Muscle Endurance During the First Year of Treatment of Polymyositis and Dermatomyositis: A Prospective Study. ( 29419464 )
2018
34
Using multi-omics methods to understand dermatomyositis/polymyositis. ( 28778709 )
2017
35
Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis. ( 28836555 )
2017
36
Pregnancy outcomes in adult patients with dermatomyositis and polymyositis. ( 29217291 )
2017
37
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. ( 28385805 )
2017
38
Extensive Dystrophic Calcinosis Cutis: A Severe Complication of Polymyositis/Systemic Sclerosis Overlap Syndrome. ( 28926465 )
2017
39
An efficacy analysis of whole-body magnetic resonance imaging in the diagnosis and follow-up of polymyositis and dermatomyositis. ( 28715432 )
2017
40
Cardiac function in patients with polymyositis or dermatomyositis: a three-dimensional speckle-tracking echocardiography study. ( 29168054 )
2017
41
Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE). ( 28931462 )
2017
42
Positive Association between ANKRD55 Polymorphism 7731626 and Dermatomyositis/Polymyositis with Interstitial Lung Disease in Chinese Han Population. ( 28470010 )
2017
43
Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis. ( 28463039 )
2017
44
Evaluation of coexisting polymyositis in feline myasthenia gravis: A case series. ( 28687435 )
2017
45
Adult morphea en coup de sabre with accompanying regional polymyositis: A separate entity? ( 28731498 )
2017
46
Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. ( 28283597 )
2017
47
Muscle ultrasound: a potential tool for detecting of fasciitis among dermatomyositis and polymyositis: Comment on article by Yoshida et al. ( 28853226 )
2017
48
T-cell receptor-mediated characteristic signaling pathway of peripheral blood T cells in dermatomyositis and polymyositis. ( 29172719 )
2017
49
Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab - durvalumab treatment. ( 28716137 )
2017
50
Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. ( 28012490 )
2017

Variations for Polymyositis

Expression for Polymyositis

Search GEO for disease gene expression data for Polymyositis.

Pathways for Polymyositis

Pathways related to Polymyositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.4 MIR155 MIR21 MIR210 MIR222
2 10.85 MIR210 MIR222
3 10.54 MIR146B MIR222

GO Terms for Polymyositis

Cellular components related to Polymyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 MIR127 MIR130A MIR132 MIR146B MIR155 MIR21

Biological processes related to Polymyositis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.71 MIR132 MIR155 MIR21
2 positive regulation of protein kinase B signaling GO:0051897 9.67 MIR132 MIR21 MIR222
3 positive regulation of epithelial to mesenchymal transition GO:0010718 9.56 MIR21 MIR222
4 positive regulation of angiogenesis GO:0045766 9.56 MIR130A MIR132 MIR21 MIR210
5 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.55 MIR146B MIR155
6 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.52 MIR155 MIR222
7 positive regulation of activated T cell proliferation GO:0042104 9.51 MIR155 MIR21
8 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.5 MIR130A MIR21 MIR222
9 positive regulation of cardiac muscle hypertrophy GO:0010613 9.48 MIR155 MIR21
10 negative regulation of regulatory T cell differentiation GO:0045590 9.46 MIR155 MIR21
11 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.43 MIR21 MIR210
12 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.4 MIR155 MIR222
13 negative regulation of cell adhesion molecule production GO:0060354 9.37 MIR155 MIR222
14 positive regulation of vascular endothelial cell proliferation GO:1905564 9.33 MIR130A MIR132 MIR21
15 miRNA mediated inhibition of translation GO:0035278 9.26 MIR132 MIR21 MIR210 MIR222
16 gene silencing by miRNA GO:0035195 9.17 MIR130A MIR132 MIR146B MIR155 MIR21 MIR210

Molecular functions related to Polymyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR130A MIR132 MIR146B MIR155 MIR21 MIR210

Sources for Polymyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....